A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia

Scandinavian Journal of Infectious Diseases

Volumn 30, Issue 4, 1998, Pages 397-404

  Norrby, S Ragnar ^a   Petermann, Wolfgang ^b   Willcox, Paul Anthony ^c   Vetter, Norbert ^d   Salewski, Erich ^e  

^a LUND UNIVERSITY   (Sweden)

^b Innere Abteilung   (Germany)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d Pulmologisches Zentrum   (Austria)

^e SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; LEVOFLOXACIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; CEFTRIAXONE; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HOSPITALIZATION; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; OFLOXACIN; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME;

EID: 0031768793     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365549850160710     Document Type: Article

References (29)

1. Davis R, Bryson HM. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994; 47: 677-700.
2. Barry AL, Fuchs PC, Allen SD, Brown SD, Jorgensen JH, Tenover FC. In-vitro susceptibility of Streptococcus pneumoniae to the D- and L-isomers of ofloxacin: interpretive criteria and quality control limits. J Antimicrob Chemother 1996; 37: 365-9.
3. Fu KP, Lafredo SC, Foleno B, Isaacson DM, Barrett JF, Tobia AJ, Rosenthale ME. In vitro and in vivo antibacterial activities of levofloxacin (L-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother 1992; 36: 860-6.
4. Klugman KP, Capper T. Levofloxacin in-vitro activity and synergistic activity in combination with other antibacterials against antibiotic-resistant S. pneumoniae and selection of resistant mutants. Proceedings of 35th ICAAC, San Francisco, USA 1995; Abstract E9.
5. Markus A, Isert D, Klesel N, Seibert G. Killing activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in vitro and in vivo. Proceedings of 35th ICAAC, San Francisco, USA 1995; Abstract E30.
6. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997; 32: 101-19.
7. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333: 1618-24.
8. Fass RJ. Aetiology and treatment of community-acquired pneumonia in adults: an historical perspective. J Antimicrob Chemother 1993; 32 Suppl A: 17-27.
9. Finch RG. The role of new quinolones in the treatment of respiratory tract infections. Drugs 1995; 49, Suppl 2: 144-51.
10. Fang G-D, Fine M, Orloff J, Arisumi D, Yu VL, Kapoor W, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine 1990; 69: 307-16.
11. Marrie TJ, Peeling RW, Fine MJ. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996; 101: 508-15.
12. Craven DE. Prevention of hospital-acquired pneumonia: measuring effect in ounces, pounds, and tons. Ann Intern Med 1995; 122: 229-31.
13. Mangi RJ, Peccerillo KM, Ryan J, Berenson C, Greco T, Thornton G, Andriole VT. Cefoperazone versus ceftriaxone monotherapy of nosocomial pneumonia. Diagn Microbiol Infect Dis 1992; 15: 441-7.
14. Hirata-Dulas CA, Stein DJ, Guay DR, Gruninger RP, Peterson PK. A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections. J Am Geriatr Soc 1991; 39: 979-85.
15. The British Thoracic Society, London. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993; 49: 346-50.
16. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections 1988. Am J Infect Control 1988; 16: 128-40.
17. Harkins RD, Albrecht R. Design and analysis of clinical trials for anti-infective drug products. Drug Infect J 1990; 24: 213-24.
18. Makuch R, Simon R. Sample size requirements for evaluating a conservative therapy. Cancer Treat Rep 1978; 62: 1037-40.
19. Plouffe JF, Herbert MT, File TM Jr, Baird I, Parsons JN, Kahn JB, Rielly-Gauvin KT, and The Pneumonia Study Group. Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Antimicrob Agents Chemother 1996; 40: 1175-9.
20. Fink MP, Snydman DR, Niederman MS, Leeper KV, Johnson RJ, Heard SO, Wunderink RG, Caldwell JW, Schentag JJ, Siami GA, Zameck RL, Haverstock DC, Reinhart HH, Echols RM, and The Severe Pneumonia Study Group. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastin. Antimicrob Agents Chemother 1994; 38: 547-57.
21. Portier H, May TH, Proust A, and The French Study Group. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1996; 37, Suppl A: 83-91.
22. Fogarty CM. A noncomparative study to evaluate the safety and efficacy of levofloxacin in the treatment of community-acquired pneumonia in adults. Proceedings of 19th ICC, Montreal, Canada 1995.
23. File TM, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41: 1965-72.
24. Conly JM, Low DE. Intravenous to oral antimicrobial stepdown therapy: improving the quality of care and reducing costs. Can J Infect Dis 1995; 6 Suppl A: A3-5.
25. Louie TJ. Intravenous to oral stepdown antibiotic therapy: another cost-effective strategy in an era of shrinking health care dollars. Can J Infect Dis 1994; 5 Suppl C: C45-50.
26. Quintiliani R, Crowe HM, Nightingale C. Transitional antibiotic therapy. Can J Infect Dis 1995; 6 Suppl A: A6-10.
27. Salewski E, Bassaris HP, Calangu S, Kitzes R, Kosmidis J, Raz R, Kompan L. Cost-minimisation analysis of sequential treatment with ofloxacin or ciprofloxacin in hospitalised patients. Pharmacoecon 1997; 11: 359-66.
28. Garber GE, McLean W, Tierney M, Pagé D. Reducing antibiotic costs; the Ottawa General Hospital experience of cost cutting, including intravenous to oral stepdown. Can J Infect Dis 1995; 6, Suppl A: 17A.
29. Jewesson P. Cost-effectiveness and value of an i.v. switch. Pharmacoecon 1994; 5 Suppl 2: 20-6.